ATHE News

Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference

Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy